ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
119.662,38
0,08%
S&P 500
5.431,60
-0,04%
US Dollar vs BRL
5,35049
0,00%
Bitcoin
66.533,82
0,52%
Brent Oil
82,275
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Vaxcyte Inc (PCVX)

  7. Vaxcyte Inc (PCVX) Notícias

PCVX

Vaxcyte (PCVX)

Vaxcyte Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PCVX
DataHoraFonteTítuloCódigoCompanhia
10/06/202417:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PCVXVaxcyte Inc
10/06/202417:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PCVXVaxcyte Inc
03/06/202417:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PCVXVaxcyte Inc
24/05/202418:05Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:PCVXVaxcyte Inc
08/05/202417:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PCVXVaxcyte Inc
08/05/202417:05GlobeNewswire Inc.Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
02/04/202417:05GlobeNewswire Inc.Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:PCVXVaxcyte Inc
04/03/202410:30GlobeNewswire Inc.Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in InfantsNASDAQ:PCVXVaxcyte Inc
27/02/202418:58Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PCVXVaxcyte Inc
27/02/202418:01GlobeNewswire Inc.Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
15/02/202418:05GlobeNewswire Inc.Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024NASDAQ:PCVXVaxcyte Inc
02/02/202420:39GlobeNewswire Inc.Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:PCVXVaxcyte Inc
01/02/202418:05GlobeNewswire Inc.Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceNASDAQ:PCVXVaxcyte Inc
31/01/202419:26Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PCVXVaxcyte Inc
31/01/202401:37GlobeNewswire Inc.Vaxcyte Announces Pricing of $750 Million Public OfferingNASDAQ:PCVXVaxcyte Inc
30/01/202418:01GlobeNewswire Inc.Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:PCVXVaxcyte Inc
29/01/202410:30GlobeNewswire Inc.Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and OlderNASDAQ:PCVXVaxcyte Inc
16/01/202418:01GlobeNewswire Inc.Vaxcyte Appoints Whitney Jones as Chief People OfficerNASDAQ:PCVXVaxcyte Inc
04/01/202418:01GlobeNewswire Inc.Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) FranchiseNASDAQ:PCVXVaxcyte Inc
04/12/202320:35GlobeNewswire Inc.VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) CandidateNASDAQ:PCVXVaxcyte Inc
29/11/202318:46Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PCVXVaxcyte Inc
28/11/202310:30GlobeNewswire Inc.Vaxcyte Appoints Jacks Lee to Board of DirectorsNASDAQ:PCVXVaxcyte Inc
27/11/202318:00GlobeNewswire Inc.Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine CandidatesNASDAQ:PCVXVaxcyte Inc
09/11/202310:30GlobeNewswire Inc.Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in AdultsNASDAQ:PCVXVaxcyte Inc
06/11/202318:03GlobeNewswire Inc.Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
31/10/202317:05GlobeNewswire Inc.Vaxcyte to Present at Upcoming Investor ConferencesNASDAQ:PCVXVaxcyte Inc
19/10/202310:29Dow Jones NewsVaxcyte Gets FDA Go-Ahead on Pneumococcal Vaccine ApplicationNASDAQ:PCVXVaxcyte Inc
19/10/202309:30GlobeNewswire Inc.Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in AdultsNASDAQ:PCVXVaxcyte Inc
16/10/202309:00GlobeNewswire Inc.Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)NASDAQ:PCVXVaxcyte Inc
19/09/202317:05GlobeNewswire Inc.Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:PCVXVaxcyte Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:PCVX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
RRRP3
3R Petroleum Oleo E Gas ... ON
BOV
TOTS3
TOTVS ON
BOV
BPAC11
BTG PACTUAL UNT
BOV
BRBI11
BR PARTNERS UNT N2
BOV
CMIN3
CSN Mineracao S.A ON
BOV
HAGA3
HAGA ON
BOV
IDIV
Dividend
BOV
PRIO3
PETRORIO ON
BOV
HOOT4
HOTEIS OTHON PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados